Familial amyloidotic polyneuropathy.

Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A (1995) 3.36

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27

Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A (1996) 1.97

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70

Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci U S A (1993) 1.65

Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys J (2000) 1.58

Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26

Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26

Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov (2015) 1.02

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain (2014) 0.96

Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol (1991) 0.94

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A (2013) 0.92

Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J (2005) 0.91

Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin. Biophys J (2006) 0.91

Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. J Am Chem Soc (2013) 0.88

A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus. EMBO J (1992) 0.87

Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry (2014) 0.85

Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83

Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-. Proc Jpn Acad Ser B Phys Biol Sci (2010) 0.82

Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid (2015) 0.81

Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol (2005) 0.80

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther (2016) 0.77

Hydrogen-bond network and pH sensitivity in human transthyretin. J Synchrotron Radiat (2013) 0.76

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies. Curr Alzheimer Res (2015) 0.75

Familial amyloidotic polyneuropathy. Trends Neurosci (1989) 0.75

Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures. Theranostics (2016) 0.75

The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy. PLoS One (2015) 0.75

A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 4.09

MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem (2000) 2.83

Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet (1993) 2.57

Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem (1998) 2.26

Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics (1989) 2.17

Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol (2004) 1.76

A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics (1990) 1.74

Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A (1984) 1.74

Autocrine induction of collagenase by serum amyloid A-like and beta 2-microglobulin-like proteins. Science (1989) 1.69

The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69

C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67

Polymorphism of human plasma thyroxine binding prealbumin. Biochem Biophys Res Commun (1983) 1.60

Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. Amyloid (1999) 1.59

Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum (1979) 1.53

"A" protein of amyloidosis. Isolation of a cross-reacting component from serum by affinity chromatography. Arthritis Rheum (1975) 1.46

Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest (1977) 1.45

Lack of association of a restriction fragment length polymorphism for serum amyloid P gene with reactive amyloidosis. Arthritis Rheum (1989) 1.45

Synthesis and secretion of serum amyloid protein A (SAA) by hepatocytes in mice treated with casein. J Immunol (1980) 1.44

The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. J Biol Chem (1993) 1.42

Partial amino acid sequence homology between an heredofamilial amyloid protein and human plasma prealbumin. J Clin Invest (1981) 1.41

Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. AJR Am J Roentgenol (1996) 1.41

Isolation and identification by sequence analysis of experimentally induced guinea pig amyloid fibrils. J Exp Med (1974) 1.39

Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest (1986) 1.38

Murine amyloid protein AA in casein-induced experimental amyloidosis. Lab Invest (1977) 1.35

Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun (1988) 1.35

Transthyretin: a review from a structural perspective. Cell Mol Life Sci (2001) 1.34

Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun (1985) 1.32

Treatment of Wegener's granulomatosis with immunosuppressive agents. Description of renal ultrastructure. Arch Intern Med (1970) 1.29

Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum (1983) 1.23

Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest (1986) 1.23

Localization of the ankyrin-binding site on erythrocyte membrane protein, band 3. J Biol Chem (1989) 1.21

Suppression of in vitro antibody response by a serum factor (SAA) in experimentally induced amyloidosis. J Exp Med (1975) 1.21

Methylprednisolone pulse therapy for nonrenal lupus erythematosus. Ann Rheum Dis (1980) 1.14

Antigenic determinants in amyloid deposits. Nature (1970) 1.13

Generalized amyloid in a family of Swedish origin. A study of 426 family members in seven generations of a new kinship with neuropathy, nephropathy, and central nervous system involvement. Ann Intern Med (1977) 1.11

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology (1996) 1.10

Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol (1991) 1.10

In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res (1992) 1.08

Fibrillar assemblage of variable segments of immunoglobulin light chains: an electron microscopic study. J Immunol (1973) 1.08

Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol (2000) 1.08

Effect of purified protein SAA on immune response in vitro: mechanisms of suppression. J Immunol (1979) 1.08

A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun (1999) 1.08

A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy. J Med Genet (1992) 1.07

Neuropathy, M components, and amyloid. Lancet (1975) 1.07

Prion proteins with different conformations accumulate in Gerstmann-Sträussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol (2001) 1.07

DMSO and colchicine therapy in amyloid disease. Ann Rheum Dis (1984) 1.07

DNA sequence evidence for polymorphic forms of human serum amyloid A (SAA). Biochem Genet (1986) 1.06

Antinuclear antibodies in systemic lupus erythematosus. Detection with horseradish-peroxidase-conjugated antibody. Ann Intern Med (1970) 1.05

Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol (1999) 1.05

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci U S A (1995) 1.03

P-component of amyloid. Isolation from human serum by affinity chromatography. Arthritis Rheum (1976) 1.02

Cerebrovascular biomodelling: a technical note. Surg Neurol (1999) 1.01

Serum amyloid protein levels in south american children with rheumatoid arthritis: a co-operative study. Ann Rheum Dis (1980) 1.01

Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta (1995) 1.01

Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122). J Lab Clin Med (1991) 1.00

Biophysical analysis of normal transthyretin: implications for fibril formation in senile systemic amyloidosis. Amyloid (2001) 0.99

Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy. Appalachian amyloid. Arthritis Rheum (1987) 0.99

Adult survival with intrahepatic portal venous gas secondary to acute gastric dilatation, with a review of portal venous gas. Clin Radiol (1985) 0.99

SAA suppression of immune response in vitro: evidence for an effect on T cell-macrophage interaction. J Immunol (1982) 0.98

Amino acid structures of multiple forms of amyloid-related serum protein SAA from a single individual. Biochemistry (1988) 0.98

Hereditary amyloidosis: detection of variant prealbumin genes by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet (1990) 0.98

Identification of a new hereditary amyloidosis prealbumin variant, Tyr-77, and detection of the gene by DNA analysis. J Clin Invest (1988) 0.97

Human serum amyloid A. Three hepatic mRNAs and the corresponding proteins in one person. J Clin Invest (1988) 0.97

Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta (1994) 0.97

Amyloid deposition in a renal transplant in familial Mediterranean fever. Ann Intern Med (1977) 0.97

Polymorphism in a kappa I primary (AL) amyloid protein (BAN). Mol Immunol (1986) 0.96

Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. Biochim Biophys Acta (1999) 0.94

Cerebellar calcification and lead. J Neurol Neurosurg Psychiatry (1985) 0.93

Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol (1999) 0.93

Amino acid sequence of a kappa I primary (AL) amyloid protein (AND). Mol Immunol (1990) 0.93

In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scand J Immunol (1995) 0.93

A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol (1999) 0.93

Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid (1998) 0.93

Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology (2003) 0.92

Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants. J Clin Endocrinol Metab (1993) 0.92

A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood (1996) 0.92

Amyloid fibril protein related to immunoglobulin lambda-chains. J Immunol (1975) 0.92

A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. J Clin Invest (1990) 0.91

Serum amyloid protein SAA, C-reactive protein and lysozyme in leprosy. Int J Lepr Other Mycobact Dis (1979) 0.91

Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheum (1986) 0.91

The Ile-84-->Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. J Biol Chem (1994) 0.91

Amino acid sequence of a lambda VI primary (AL) amyloid protein (WLT). Scand J Immunol (1985) 0.91

SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders. Lack of association with amyloid disease. J Rheumatol (1981) 0.91

Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest (1994) 0.91

Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection, and malignancy as compared to normal serum. J Lab Clin Med (1979) 0.90

Induction of beta-sheet structure in amyloidogenic peptides by neutralization of aspartate: a model for amyloid nucleation. J Mol Biol (1999) 0.90

Diffuse fasciitis and eosinophilia with symmetric polyarthritis. Ann Intern Med (1980) 0.89

Fractionation of primary amyloid fibrils. Characterization and chemical interaction of the subunits. Biochim Biophys Acta (1977) 0.89

Diagnosis of familial amyloidotic polyneuropathy in France. Clin Genet (1990) 0.89

A 25,000 molecular weight protein constituent of human amyloid fibrils related to amyloid protein AA. Arch Biochem Biophys (1975) 0.89

Renal amyloidosis with a frame shift mutation in fibrinogen aalpha-chain gene producing a novel amyloid protein. Blood (1997) 0.88

Cardiac amyloidosis associated with the transthyretin Ile122 mutation in a Caucasian family. Amyloid (2001) 0.88

Production and functional analysis of normal and variant recombinant human transthyretin proteins. J Biol Chem (1992) 0.88

A transthyretin variant (alanine 71) associated with familial amyloidotic polyneuropathy in a French family. J Med Genet (1993) 0.88

Erosive arthritis in hereditary amyloidosis. Arthritis Rheum (1983) 0.88

Biochemical characterization of a neuroserpin variant associated with hereditary dementia. Am J Pathol (2001) 0.87

Serum amyloid A in carcinoma of the lung. Cancer (1986) 0.87

Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol (1996) 0.86

Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2. Biochem J (1997) 0.86

Antigenicity and cross-reactivity of denatured fibril proteins of primary, secondary, and myeloma associated amyloids. J Lab Clin Med (1975) 0.86